ArticleJournal of the American Academy of Dermatology2018
Psoriasis and the risk of diabetes: A prospective population-based cohort study.
Article in Journal of the American Academy of Dermatology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 81 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
81 citing papers in PubMed, 3 syntheses or guidelines pooled it, 132 citations in OpenAlex.
- Causal Relationship and Shared Genetic Loci between Psoriasis and Type 2 Diabetes through Trans-Disease Meta-Analysis.The Journal of investigative dermatology · 2021Pooled it
- Associations between COVID-19 and skin conditions identified through epidemiology and genomic studies.The Journal of allergy and clinical immunology · 2021Pooled it
- National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 1.Journal of the American Academy of Dermatology · 2020Guideline
- A Randomized Placebo-Controlled Trial of Secukinumab on Aortic Vascular Inflammation in Moderate-to-Severe Plaque Psoriasis (VIP-S).The Journal of investigative dermatology · 2020Trial
- A Phase IV, Randomized, Double-Blind, Placebo-Controlled Crossover Study of the Effects of Ustekinumab on Vascular Inflammation in Psoriasis (the VIP-U Trial).The Journal of investigative dermatology · 2020Trial
- Trial
- Increased Risk of Psoriasis in Young Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease: A Retrospective Cohort Study.Annals of dermatology · 2026Article
- Phenylalanine exacerbates psoriasiform inflammation through NF‑κB‑mediated dendritic cell activation and Th17 polarization.International journal of molecular medicine · 2026Article
- Assessing the association of type 2 diabetes with skin health status: a study of the Northern Finland Birth Cohort 1966.BMJ open · 2026Article
- Diabetic Wound Vasculopathy and Neuropathy: Spotlight on Wound Lipid Signaling.Advances in wound care · 2026Review
- Efficacy and Safety of Tildrakizumab for Moderate-to-Severe Plaque Psoriasis with Diabetes: Pooled Subgroup Analysis of reSURFACE 1 and reSURFACE 2.Dermatology and therapy · 2026Article
- Review
- Association Between Psoriasis Risk and Body Mass Index and Waist Circumference in Diabetes: A Population-Based Cohort Study.Annals of dermatology · 2026Article
- Plasma Galectin-7 (Gal-7) and Galectin-8 (Gal-8) as Emerging Biomarkers in Psoriasis: Associations with Disease Activity and Metabolic Status.Metabolites · 2026Article
- Long-Term Risk of Type 2 Diabetes Associated With Topical Corticosteroid Use: A Nationwide Population-Based Cohort Study in Korea.Advances in pharmacological and pharmaceutical sciences · 2026Article
- Associations Between Psoriasis and Endocrine Diagnoses in a Tertiary-Center Electronic Health Record Database: A Cross-Sectional Study.Clinical, cosmetic and investigational dermatology · 2026Article
- Article
- Psoriasis and type 2 diabetes mellitus: epidemiology, shared mechanisms, and therapeutic implications: a narrative review.Frontiers in medicine · 2026Review
- The effects of GLP-1RA on inflammatory skin diseases: A comprehensive review.Journal of the European Academy of Dermatology and Venereology : JEADV · 2025Review
- The co-impact of diabetes and psoriasis on mortality risk for all causes and specific causes.Scientific reports · 2025Article
21 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundData evaluating the impact of objectively measured psoriasis severity on type 2 diabetes mellitus (T2DM) risk are lacking.
objectiveTo determine the risk for T2DM in patients with psoriasis compared with that in adults without psoriasis, stratified by categories of directly assessed body surface area (BSA) affected by psoriasis.
methodsA prospective, population-based, cohort study from the United Kingdom in which 8124 adults with psoriasis and 76,599 adults without psoriasis were followed prospectively for approximately 4 years.
resultsThere were 280 incident cases of diabetes in the psoriasis group (3.44%) and 1867 incident cases of diabetes in those without psoriasis (2.44%). After adjustment for age, sex and body mass index, the hazard ratios for development of incident diabetes were 1.21 (95% confidence interval [CI], 1.01-1.44), 1.01 (95% CI, 0.81-1.26), and 1.64 (95% CI, 1.23-2.18) in the groups with 2% or less of their BSA affected, 3% to 10% of their BSA affected, and 10% or more of their BSA affected compared with in the groups without psoriasis, respectively (P = .004 for trend). Worldwide, we estimate an additional 125,650 new diagnoses of T2DM per year in patients with psoriasis as compared with in those without psoriasis. LIMITATIONS: Relatively short-term follow-up and exclusion of prevalence cases, which may have masked associations in patients with less extensive psoriasis.
conclusionClinicians may measure BSA affected by psoriasis to target diabetes prevention efforts for patients with psoriasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.